- Report
- September 2026
- 225 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 275 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 369 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 175 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 383 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 214 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 293 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 289 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 246 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- September 2026
- 369 Pages
Global
From €5218EUR$5,850USD£4,474GBP
- Report
- August 2026
- 130 Pages
Global
From €4237EUR$4,750USD£3,632GBP
- Report
- July 2026
- 110 Pages
Global
From €4237EUR$4,750USD£3,632GBP
- Report
- July 2026
- 118 Pages
Global
From €4237EUR$4,750USD£3,632GBP
- Report
- July 2026
- 108 Pages
Global
From €4237EUR$4,750USD£3,632GBP
- Report
- May 2026
- 130 Pages
Global
From €4237EUR$4,750USD£3,632GBP
- Report
- January 2026
- 129 Pages
Global
From €3523EUR$3,950USD£3,021GBP
- Report
- January 2026
- 145 Pages
Global
From €3523EUR$3,950USD£3,021GBP
- Report
- January 2026
- 148 Pages
Global
From €3523EUR$3,950USD£3,021GBP
- Report
- February 2026
- 160 Pages
Global
From €2961EUR$3,320USD£2,539GBP
€3702EUR$4,150USD£3,174GBP
- Report
- November 2025
- 160 Pages
Global
From €2819EUR$3,160USD£2,416GBP
€3523EUR$3,950USD£3,021GBP

The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less Read more